Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Adare Pharmaceuticals, Inc.
EIR
•Adare Pharmaceuticals, Inc.•May 19, 2017

Adare Pharmaceuticals, Inc. – FDA EIR, May 19, 2017

Record Details

An FDA surveillance inspection of Adare Pharmaceuticals Inc.'s Vandalia, OH facility was conducted from May 15-19, 2017. This review, aligning with FDA's drug manufacturing inspection guidelines, focused on the company's operations as a contract manufacturer of oral solid dosage forms. The inspection covered critical aspects including quality, laboratory, and production systems. Significantly, the inspection concluded without the issuance of an FDA Form 483, Inspectional Observations, and was ultimately classified as "No Action Indicated" (NAI). However, two key areas were discussed with management. Concerns were raised regarding the documentation of a "continuous improvement plan" intended to address raw material lot variability leading to dissolution failures. While the firm had successfully implemented internal blending to mitigate recent issues, the formal supplier improvement plan lacked comprehensive detail. Additionally, the inspection team noted a persistent issue with foreign particles in a critical ingredient blend from a supplier. Adare Pharmaceuticals acknowledged these observations, explaining their proactive internal measures such as enhanced incoming material testing and metal detection. They also confirmed ongoing efforts with the supplier to implement facility upgrades to resolve the foreign particle contamination. Management agreed to enhance the documentation for future improvement plans. No formal violations or immediate regulatory actions were required from the FDA.

Company
Adare Pharmaceuticals, Inc.
Inspection date
May 19, 2017
Product type
drugs
Office
Cincinnati District Office
People
  • Juan Pablo Gutierrez (recipient)
  • Andrea Engle (company_representative)
  • Lauren N. Smith (investigator)
  • Chad Alexander (company_representative)
  • James F. Horger (company_representative)
View Company Profile

ID · 6ef3867a-34a2-48d9-a556-ef535c36403d

Other documents for Adare Pharmaceuticals, Inc.
  • 483 - 2025-02-25February 25, 2025
  • EIR - 2025-02-25February 25, 2025
  • EIR - 2019-01-25January 25, 2019
  • EIR - 2018-07-11July 11, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Adare Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.